by Suzanne Potter
The French pharmaceutical company Amolyt Pharma and the Japanese company PeptiDream recently announced they will team up to develop therapeutic peptides for the treatment of acromegaly.
Amolyt, based in Lyon and in Boston, has experience in this field. Currently they have a program in development for hypoparathyroidism that has recently received orphan drug status from the U.S. Food and Drug Administration. Amolyt is also working on a second peptide for glucose and fat metabolism, which is in the preclinical stage.
PeptiDream, based in Kanagawa, is a large company with teams of peptide chemists that is partnering Amolyt to move their discovery forward.